Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?

Journal of Clinical Virology

Volumn 22, Issue 3, 2001, Pages 271-278

  Mijch, Anne M ^a   Hoy, Jennifer ^a   Watson, Kerrie ^a   Dunne, Amanda ^b   Crowe, Suzanne ^b   Wesselingh, Steven L ^a  

^a MONASH UNIVERSITY   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

Antiretroviral therapy; CD4 lymphocyte count; HIV viral load; HIV AIDS; Outcome measures

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AUSTRALIA; BLOOD LEVEL; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE MARKER; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; RNA ANALYSIS; TREATMENT OUTCOME; VIRUS DETECTION;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034843105     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(01)00199-8     Document Type: Conference Paper

References (33)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
2. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy
3. HIV disease progression in Australia at the time of combination antiretroviral therapies
4. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
5. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
6. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study
7. Costs of HIV medical care in the era of highly active antiretroviral therapy
8. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
9. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
10. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less
11. Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection
12. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
13. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital
14. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
15. Reduction in hospitalisation costs, morbidity, disability, and mortality in patients with aids treated with protease inhibitors
16. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective Cohort Study. Swiss HIV Cohort Study
17. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
18. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
19. Self-reported antiretroviral adherence correlates with HIV viral load and declines over time
20. + lymphocytes as prognostic markers of HIV-1 infection
21. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
22. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
23. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
24. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal free centre for HIV medicine
25. AIDS across Europe, 1994-98: The EuroSIDA study
26. Changing patterns of mortality across Europe in patients infected with HIV-1
27. The HIV outpatient study investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
28. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
29. Immune control of HIV-1 after early treatment of acute infection
30. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
31. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
32. Viral drug resistance, adherence and pharmacokinetic indices in HIV-1 infected patients on successful and failing protease inhibitor based HAART